Coordination of capsule assembly and cell wall biosynthesis in <em>Staphylococcus aureus</em> by Rausch M et al.
ARTICLE
Coordination of capsule assembly and cell wall
biosynthesis in Staphylococcus aureus
Marvin Rausch 1,2, Julia P. Deisinger1,2, Hannah Ulm1, Anna Müller 1, Wenjin Li3, Patrick Hardt1,
Xiaogang Wang4, Xue Li4, Marc Sylvester 5, Marianne Engeser 6, Waldemar Vollmer7, Christa E. Müller 3,
Hans Georg Sahl8, Jean Claire Lee4 & Tanja Schneider1,2
The Gram-positive cell wall consists of peptidoglycan functionalized with anionic glycopo-
lymers, such as wall teichoic acid and capsular polysaccharide (CP). How the different cell
wall polymers are assembled in a coordinated fashion is not fully understood. Here, we
reconstitute Staphylococcus aureus CP biosynthesis and elucidate its interplay with the cell
wall biosynthetic machinery. We show that the CapAB tyrosine kinase complex controls
multiple enzymatic checkpoints through reversible phosphorylation to modulate the con-
sumption of essential precursors that are also used in peptidoglycan biosynthesis. In addition,
the CapA1 activator protein interacts with and cleaves lipid-linked CP precursors, releasing
the essential lipid carrier undecaprenyl-phosphate. We further provide biochemical evidence
that the subsequent attachment of CP is achieved by LcpC, a member of the LytR-CpsA-Psr
protein family, using the peptidoglycan precursor native lipid II as acceptor substrate. The
Ser/Thr kinase PknB, which can sense cellular lipid II levels, negatively controls CP synthesis.
Our work sheds light on the integration of CP biosynthesis into the multi-component
Gram-positive cell wall.
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The bacterial cell envelope is a complex multilayeredstructure consisting of peptidoglycan (PG), which inGram-positive bacteria is densely decorated with glyco-
polymers such as wall teichoic acid (WTA) and capsular poly-
saccharide (CP). The coordinated synthesis and assembly of
these polymers is pivotal for maintenance of cell wall architecture
and function1. In contrast to the biosyntheses of PG and
WTA, for which the individual enzymatic reactions have
already been characterized in vitro2,3, the biochemistry under-
lying capsule formation in Gram-positive bacteria is not well
understood. Even more so, it is largely unknown how the dif-
ferent cell wall synthesis pathways, which share building
blocks and membrane carriers, function in a coordinated and
integrated fashion.
In the case of Staphylococcus aureus, an important opportu-
nistic pathogen4, the expression of a polysaccharide capsule
contributes substantially to the ability to cause invasive disease5–7.
Serotype 5 and 8 capsular polysaccharide (CP5 and CP8) types
are dominant among clinical isolates6. S. aureus USA300, which
is prevalent in the United States, lacks a capsule due to several
conserved mutations within the cap5 locus8. However, the
majority of USA300-associated infections involved superficial
wounds or abscesses9, and USA300 isolates are not common
outside of North America10. Among predominant methicillin-
resistant S. aureus clones worldwide are the CP8+ lineages
ST1, ST30, ST59, ST80, and ST239 and the CP5+ lineages ST5
and ST22.
CP5 and CP8 share similar trisaccharide repeating units,
which are identical in monosaccharide composition and
sequence, only differing in the glycosidic linkages between the
sugars and the sites of O-acetylation11.
The CP5 biosynthetic gene cluster comprises 16 genes (cap5A–
cap5P; Fig. 1a)12 encoding for proteins involved in polymer
biosynthesis7,13,14, acetylation15, transport, and the regulation of
CP production16,17. Database homology searches with amino
acid sequences of cap5 operon gene products allowed for the
prediction of individual enzymatic functions and the proposal of
a pathway for capsule (CP) biosynthesis in S. aureus18.
Within this pathway (Fig. 1b), synthesis of the soluble building
blocks occurs in the cytoplasm via three distinct reaction
cascades, through which the universal cell envelope substrate
UDP-D-N-acetylglucosamine (UDP-D-GlcNAc), is converted
into the three different nucleotide-coupled sugars UDP-N-acetyl-
D-fucosamine (UDP-D-FucNAc), UDP-N-acetyl-L-fucosamine
(UDP-L-FucNAc) and UDP-N-acetyl-D-mannosaminuronic acid
(UDP-D-ManNAcA). The synthesis of the first soluble precursor
UDP-D-FucNAc is allegedly catalyzed in a two-step process by
the enzymes CapD and CapN. Only recently, the integral mem-
brane protein CapD was shown to function as a 4,6-dehydratase,
which generates the intermediate UDP-2-acetamido-2,6-dideoxy-
D-xylo−4-hexulose19, proposed to be further converted to UDP-
D-FucNAc by the action of the membrane-associated reductase
CapN, though experimental evidence is lacking so far. Subse-
quently, CapM is supposed to transfer the phosphosugar moiety
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Fig. 1 S. aureus capsule biosynthesis. a S. aureus capsule (CP5) biosynthesis gene cluster (NWMN_0095–0110). b Model for the capsule (CP) biosynthesis
pathway in S. aureus and its regulation by the tyrosine kinase complex CapA1B1. C55P, undecaprenyl-phosphate; GlcNAc, N-acetyl-glucosamine; FucNAc,
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arrow indicates reaction reversibility
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of UDP-D-FucNAc to the membrane-anchored lipid carrier
undecaprenyl-phosphate (C55P), yielding lipid Icap.
The second cytoplasmic reaction cascade generating the
soluble precursor UDP-L-FucNAc involves the enzymes CapE,
CapF and CapG, the enzymatic functions of which have already
been elucidated biochemically13. The transferase CapL is assumed
to further attach L-FucNAc to lipid Icap leading to the formation
of the second CP lipid intermediate, lipid IIcap.
The third nucleotide-activated monosaccharide required for
CP5 production, UDP-D-ManNAcA, is generated by the epi-
merase CapP and the dehydrogenase CapO7,14. The transmem-
brane protein CapI has been proposed to transfer the ManNAcA
moiety to lipid IIcap, thereby generating the final capsule pre-
cursor lipid IIIcap. The C55P-coupled trisaccharide is most likely
further modified by the putative acetyltransferase CapH15, which
catalyzes the O-acetylation of L-FucNAc residues in position C3
in CP5 strains11. The complete, modified precursor is then
translocated to the outer surface of the cell membrane, where
polymerization is assumed to take place. These processes are
proposed to be facilitated by the putative flippase CapK
and the polymerase CapJ, respectively12,18. The attachment of
CP precursors to the MurNAc (N-acetylmuramic acid) moiety
of peptidoglycan is achieved by a yet unknown mechanism
possibly involving a member of the LCP (LytR-CpsA-Psr) family
of proteins20,21. This process likely releases the lipid carrier C55P,
which enters new synthesis cycles.
The fact that the undecaprenyl-phosphate carrier is found
in limited amounts within the cell22 and required for the bio-
syntheses of diverse cell envelope components, like CP, WTA and
PG2,3,18, makes a well-orchestrated spatial and temporal regula-
tion of these processes crucial for the viability of the cell. The
consequences arising from perturbation of this balanced biosyn-
thetic network have been well exemplified for WTA biosynthesis.
Interference with late WTA biosynthesis steps has been shown to
be lethal, although the polymer per se is not crucial for viability23.
Similarly, late stage genes are conditionally essential since they are
dispensable for viability in an early gene (tarO or tarA) deletion
background, a phenomenon referred to as the “essential gene
paradox”24. Inhibition of late WTA biosynthesis steps causes
the accumulation of dead-end lipid-linked intermediates and
thus depletes the cellular pool of C55P to critical levels impeding
peptidoglycan biosynthesis, resulting in cell death25.
In S. aureus, the regulation of CP biosynthesis is not only
achieved by differential gene expression26–28, but has additionally
been linked to tyrosine phosphorylation16,17. Bacterial tyrosine
kinases (BY-kinases) are widespread in bacteria and have
multifaceted roles in bacterial exopolysaccharide production29.
BY-kinases belong to the family of P-loop containing kinases30,
whereby “P-loop” designates a characteristic amino acid sequence
resembling the Walker A nucleotide binding motif. BY-kinases
of Firmicutes are composed of two interacting polypeptides,
a transmembrane activator protein and a cytoplasmic BY-
kinase31. The cytoplasmic kinase carries a C-terminal tyrosine
cluster that undergoes autophosphorylation in the presence of
ATP. Based on studies in S. aureus and Streptococcus pneumo-
niae, the cytoplasmic kinase protein alone is not sufficient for
phosphotransfer, but has to interact with the C-terminus of the
transmembrane adaptor to undergo autophosphorylation16,32,33.
Concomitantly, phosphate groups can be transferred to tyrosine
residues of target proteins, thus modulating their activity.
Two triplets of adjacent genes encoding for a transmembrane
adaptor, a cytoplasmic BY-kinase, and a cognate phosphotyrosine
phosphatase were identified in the genome of S. aureus ser-
otype 5: The capA1/capB1/capC1 triplet (also referred to
cap5A/cap5B/cap5C) is located at the 5ʹ-end of the cap5 operon
(Fig. 1a), whereas the highly similar capA2/capB2/capC2 triplet
is found elsewhere on the bacterial chromosome12,16. So far,
the cellular roles of the distinct CapAB complexes are not fully
understood. Particularly, the nature of the stimulus that triggers
CapAB signaling and the exact mode of signal transduction are
still elusive.
In this study, we functionally reconstitute the entire CP bio-
synthetic reaction cascade generating the three membrane-
anchored CP precursors lipid Icap, lipid IIcap and lipid IIIcap,
allowing us to identify crucial enzymatic check points, which are
regulated by the tyrosine kinase CapA1B1 complex to control
the consumption of essential precursors. Reconstitution of the
membrane anchored CapA1 adaptor protein further reveals a yet
elusive function. We show that CapA1 is a dual-function kinase
activator/phosphodiesterase protein crucial for signaling and
processing of the CP polymer. CapA1 interacts with lipid-bound
CP precursors to catalyze the cleavage of the pyrophosphate
linkage, releasing the essential lipid carrier C55P. Moreover, we
elucidate the principles of CP attachment to murein precursors in
Gram-positive bacteria. We show that the transfer of the capsular
phosphosugar moiety is conducted by a member of the LCP
protein family and identify the acceptor substrate. We provide
biochemical evidence that the attachment of the anionic pre-
cursor likely occurs on the level of the lipid-linked peptidoglycan
precursor lipid II, and is facilitated in the presence of CapA1,
indicating its cooperative functioning with LCP proteins.
Results
In vitro reconstitution of capsule biosynthesis. Homology
searches with CapD and CapN suggested that both proteins
are involved in the synthesis of the first soluble capsule precursor
UDP-D-FucNAc18. More recently, CapD was characterized at
the molecular level, and the enzymatic product was shown
to be UDP-2-acetamido-2,6-dideoxy-D-xylo−4-hexulose19. CapN
is proposed to further convert the CapD reaction product
to UDP-D-FucNAc by stereospecific reduction of the C-4 keto
group18.
As confirmed by capillary electrophoresis (CE) and mass
spectrometry (MS), purified CapN (Supplementary Figure 1)
catalyzed the NADPH-dependent conversion of the intermediate
UDP-2-acetamido-2,6-dideoxy-D-xylo−4-hexulose to a sugar
nucleotide species having a molecular mass of m/z 590.4 for
the negatively charged molecule, consistent with the formation of
UDP-D-FucNAc (Supplementary Figure 2). The subsequent
transfer of the phosphosugar moiety of UDP-D-FucNAc to the
lipid anchor C55P is thought to be catalyzed by the polyprenyl-
phosphoglycosyltransferase CapM, to initiate the assembly of
the lipid-anchored trisaccharide repeating units18. Incubation
of purified CapM protein with C55P and UDP-D-[14C]FucNAc
revealed the formation of a new radiolabeled lipid species, not
present in the negative control (Fig. 2a). In comparison to C55P
(Fig. 2a, lane 1; Rf= 0.95), migration of the lipid product was
retarded (lane 3; Rf= 0.87), consistent with the addition of a
sugar moiety. The product displayed the same Rf value as
determined for the WTA lipid intermediate undecaprenyl-
pyrophosphoryl-D-GlcNAc (lipid III), which is structurally very
similar to the proposed first CP lipid intermediate34. The newly
formed purified lipid intermediate had a mass of m/z 1112.7058
for the negatively charged molecule (Fig. 2b), which is consistent
with the calculated neutral mass for undecaprenyl-pyropho-
sphoryl-D-FucNAc (lipid Icap) of 1113.7162. Moreover, the GT-B
type35 glycosyltransferase CapL was able to use lipid Icap as
acceptor substrate and to catalyze the addition of the second 14C-
labeled sugar moiety L-FucNAc, yielding lipid IIcap (Fig. 2a,
lane 4; Rf= 0.83). Mass spectrometry analysis of lipid IIcap
revealed a mass of m/z 1299.7896 [M–H]− matching the
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calculated neutral mass of m/z 1300.801 for undecaprenyl-
pyrophosphoryl-D-FucNAc-L-FucNAc.
Conversion to the ultimate lipid-linked CP precursor lipid
IIIcap was achieved by the attachment of a 14C-D-ManNAcA
residue to lipid IIcap, catalyzed by the glycosyltransferase CapI
(Fig. 2a, lane 5; Rf= 0.53). Mass spectrometric analysis of
lipid IIIcap did not yield any signal, presumably due to reduced
ionization with addition of further sugar moieties. However, in
line with the altered migration behavior of the different CP
intermediates on TLC (Fig. 2a, lanes 3–5) resulting from the
consecutive sugar residue addition, the lantibiotic nisin formed
extraction-stable complexes with all C55P-containing CP pre-
cursors further validating their identity (Fig. 2a, lanes 6–8). Taken
together, these findings confirm the proposed functions of the
different glycosyltransferases (GT) and demonstrate that CapM
functions as priming GT, initiating the synthesis of membrane-
bound CP precursors by coupling the first sugar moiety to the
lipid carrier C55P.
CapM is homologous to a wide range of GTs from various
pathogens (Supplementary Figure 3a), which catalyze the transfer
of UDP-activated sugars to C55P36,37. Prediction of transmem-
brane topology (http://www.cbs.dtu.dk/services/TMHMM/) and
comparison with hydrophobicity plots (ProtScale38) of homo-
logous GTs predicts that CapM is anchored to the cytoplasmic
membrane by a 28-amino acid long α-helical transmembrane
domain that is linked to a large C-terminal catalytic domain
located in the cytoplasm (Supplementary Figure 3b). In contrast
to the in silico predicted single-pass transmembrane (TM)
helix geometry, structural analysis of the homologous PglC
of Campylobacter concisus suggests that the TM segment adopts
an unusual architecture37. Structural modelling of CapM revealed
a similar architecture (Supplementary Figure 3c), in which the
TM segment is broken into two helices (A and B) with an
interhelix angle of 118° by a Ser-Pro motif (Supplementary
Figure 3c), suggesting a similar membrane embedment as
PglC. Shared structural features further include a conserved Arg
residue (Arg3) positioned at the membrane interface as well as
a catalytic Asp-Glu dyad and a strictly conserved PRP motif
(residues 110–112 in CapM) in the cytoplasmic GT domain,
involved in Mg2+ and substrate binding, respectively37 (Supple-
mentary Figure 3). CapM activity in vitro depends on the
presence of MgCl2, and was completely lost in the presence of
EDTA (Supplementary Figure 4a), as reported for homologous
glycosyltransferases36,37,39.
Interestingly, CapM was inhibited in the presence of
tunicamycin (Supplementary Figure 4a), a nucleoside antibiotic
shown to inhibit members of the UDP-HexNAc-1-phosphate
transferase family (i.e., WecA, MraY or TarO) through
competitive binding to the DDxxD Mg2+-binding site39.
Tunicamycin had an IC50 of 129 µM for CapM, which is in the
range determined for PglC of C. jejuni (IC50= of 100 μM)40. The
lower potency of tunicamycin for these monotopic GTs compared
to the polytopic WecA (IC50 of 11 nM), MraY (IC50 of ~22.5 μM)
or TarO (IC50 of~59 nM) may likely result from the distinct
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Fig. 2 Synthesis of CP lipid intermediates. Glycosyltransferases (GT) CapM, CapL and CapI catalyze the in vitro synthesis of CP lipid intermediate lipid Icap
(C55PP-D-FucNAc), lipid IIcap (C55PP-D-FucNAc-L-FucNAc) and lipid IIIcap (C55PP-D-FucNAc-L-FucNAc-D-ManNAcA), respectively. a Purified GTs were
incubated with the respective purified acceptor lipid substrate in the presence of radiolabeled UDP-activated sugars. After extraction with BuOH/PyrAc,
synthesis products were analyzed by TLC and phosphoimaging. Counterstain with iodide (lane 1) was used to visualize the migration behavior relative to
C55P. Nisin, known to bind to the pyrophosphate-sugar moiety of cell wall lipid intermediates was added posterior and formed complexes with all lipidcap
intermediates that are not extracted from the reaction mixture. Heat-inactivated CapM was used as a negative control. b ESI-MS-analysis of lipid Icap and
lipid IIcap. The peaks at m/z 1112.70 and 1299.78 correspond to the negatively charged lipid Icap and lipid IIcap molecules, respectively. c Structure of the
ultimate CP lipid intermediate lipid IIIcap. Sugar residues are colored: D-FucNAc (orange), L-FucNAc (red), D-ManNAcA (purple)
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architectures and catalytic sites. Since we observed a major impact
of anionic phospholipids (dioleoylphosphatidylglycerol and
cardiolipin) on the enzymatic activity of CapM, we further
investigated the effect of different detergents. However, CapM
showed lower activity in the presence of detergents or DMSO
indicating that the enzyme preferred the native phospholipid
environment (Supplementary Figure 4b).
CapAB phosphorylation positively modulates CapM and CapE
activity. Full-length integral membrane proteins CapA1 and
CapA2 and cytoplasmic kinases CapB1 and CapB2 were over-
expressed as His6-tag fusion proteins, purified by Ni-NTA
chromatography (Supplementary Figure 1), and utilized to
reconstitute CapAB tyrosine kinase activity in vitro in the
presence of γ-labeled [33P]ATP. CapB2 autophosphorylation was
effectively activated by full-length CapA1 or CapA2 (Fig. 3a)
producing a single radiolabeled band with an apparent molecular
mass of 25.3 kDa, corresponding to phosphorylated CapB2
(lanes 3 & 4). In contrast, the negative control in which a
CapA activator was absent (Fig. 3a, lane 1 and 2, Supplementary
Figure 5a) showed no autophosphorylation. In line with previous
findings16, phosphorylation of the individual kinase protein
CapB1 was neither observed with CapA1 nor with CapA2
(Fig. 3a, lanes 5 & 6, Supplementary Figure 5a, lanes 6 & 7).
However, when CapB1 was fused to its cognate activator
CapA1, the recombinant chimera CapAB full-length fusion pro-
tein (50.2 kDa) efficiently autophosphorylated in the presence
of γ-labeled [33P]ATP, demonstrating functionality of CapB1
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Fig. 3 Tyrosine phosphorylation positively controls CapM and CapE activity. a CapAB autokinase activity was assayed in the presence of [33P]ATP using
either native proteins or kinase activator CapA1 and tyrosine kinase CapB1 fused into a single polypeptide (CapA1B1fus). Phosphotransfer was analyzed by
SDS-PAGE and phosphoimaging. b CapM and CapE are phosphorylated by the CapA1B1fus tyrosine kinase complex. Putative target proteins (3 µg) were
assayed for phosphotransfer in the presence and absence of CapA1B1fus. CapA1B1fus, 50.2 kDa; CapB2, 25.3 kDa; CapE, 38.6 kDa; CapD, 69.1 kDa; CapM,
21 kDa; CapN, 33.7 kDa. c Impact of CapA1B1 kinase activity on CapM glycosyltransferase activity. CapM was incubated in presence of either active
CapA1B1 (light grey) or heat-inactivated CapA1B1 (dark grey) with UDP-D-[14C]FucNAc and C55P. After extraction with BuOH/PyrAc, reactions were
analyzed by TLC and phosphoimaging. d Topology and CapAB phosphorylation site (arrow) of CapM. The protein is anchored in the membrane by
one reentrant transmembrane domain. The catalytic domain is located in the cytoplasm. Sequence alignment of homologous proteins containing the
conserved Tyr phosphorylation site (red) is boxed. (from top to bottom: S. aureus, Salmonella enterica, Campylobacter concisus, Streptococcus pneumoniae and
Bacteroides fragilis). e Impact of CapA1B1 kinase activity on CapE-mediated substrate conversion. CapE was incubated in presence of either active CapA1B1
(light grey) or heat-inactivated CapA1B1 (dark grey) with UDP-D-GlcNAc. Reactions were analyzed by CE. f Mapping of CapE phosphorylation sites. Tyr
phosphorylation sites are marked by arrows. Cofactor binding site, substrate-binding site and the mobile loop are marked blue, yellow and red, respectively.
The active site motif MxxxK (stars) and the cofactor binding motif TGxxGxxG (circles) are highlighted. A sequence alignment of the mobile latch (red) of
selected homologous proteins from different species is boxed (from top to bottom: S. aureus, Bacillus cereus, Streptococcus pneumoniae, Enterococcus faecium,
Pseudomonas aeruginosa). Experiments were performed in triplicate. The error bars represent the ± standard deviation (SD) from three biological replicates.
Statistical significance was analyzed by an unpaired t test (***p < 0.005)
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(Fig. 3a, lane 7). A full-length CapA2B2 fusion protein, which was
constructed for reasons of comparison, showed comparable
autokinase activity (lane 8). This finding contradicts recent sug-
gestions that CapB1 might be a pseudokinase devoid of catalytic
activity41.
CapA1B1-mediated phosphotransfer on putative target pro-
teins involved in CP biosynthesis revealed tyrosine phosphoryla-
tion of the glycosyltransferase CapM (21 kDa) and the
dehydratase CapE (38.6 kDa) (Fig. 3b, Supplementary Figure 5b).
In contrast, recombinant CapD, CapN, CapF, CapG or CapL
were not phosphorylated (Fig. 3b, Supplementary Figure 5c). The
opposing PHP class phosphatases CapC1 and CapC2 were
able to antagonistically dephosphorylate CapB kinase and target
proteins (Supplementary Figure 5d).
Phosphorylation of CapM by the CapA1B1 fusion increased lipid
Icap synthesis 4-fold (Fig. 3c), showing that CapAB-mediated
signaling stimulates the priming step of CP biosynthesis in S. aureus
by enhancing the rate of CapM-catalyzed glycosyl transfer and thus
likely controlling the consumption of the shared carrier C55P.
In silico phosphorylation site prediction (NetPhos 3.1)42
identified tyrosines 75 and 157 as putative phosphosites in CapM
(Fig. 3d). The highly conserved Tyr157 appears to be the primary
phosphorylation site in CapM, since tyrosine phosphorylation
and the concomitant stimulatory effect on the catalytic activity
was completely abolished in the CapM_Y157F mutant (Supple-
mentary Figure 6a,b). In contrast, changing Tyr75 to Phe had
only a minor effect on the protein’s ability to be catalytically
activated by CapA1B1-mediated phosphotransfer. Both mutant
proteins retained catalytic activity comparable to wild-type CapM
in the absence of CapA1B1 (Supplementary Figure 6b) showing
that Tyr157 represents the crucial regulatory CapAB phosphor-
ylation site on CapM.
The CapA1B1-mediated stimulation of CapM activity is
also reflected by enzyme kinetics, revealing a Km value
of 2,309 ± 311.8 µM for UDP-D-FucNAc and a Vmax value of
0.5559 ± 0.02645 pmol min−1 μg−1 in the absence of CapA1B1
and a lowered Km value of 996.2 ± 136.2 µM and an increased
Vmax of 1.0688 ± 0.0358 pmol min−1 μg−1 in the presence of
CapA1B1 (Supplementary Figure 6c). Moreover, a CapM
phosphomimetic in which Tyr157 was exchanged to Glu
displayed a Km value of 1383 ± 267.3 µM and a Vmax value
of 0.8625 ± 0.04708 pmol min−1 μg−1 in the absence of CapA1B1,
substantiating the stimulatory impact of CapM phosphorylation
on Tyr157 (Supplementary Figure 6c).
In vitro kinase assays further identified CapE as a CapA1B1
target (Fig. 3e). Tryptic fragments of in vitro phosphorylated
CapE were analyzed by nanoscale liquid chromatography coupled
to tandem mass spectrometry (nanoLC-MS/MS), and Tyr76
of the CapE protein was found to be phosphorylated (Supple-
mentary Figure 7a). This residue is located in proximity to the
conserved TGxxGxxG motif required for cofactor binding and to
the MxxxK catalytic site43 (Fig. 3f). Three other phosphotyrosine
residues (Tyr290, Tyr293 and Tyr329), were mapped to a
C-terminal loop of CapE (Fig. 3f; Supplementary Figure 7a).
In CapE in vitro assays with active CapAB, the conversion of
UDP-D-GlcNAc was increased by 40%, demonstrating that
the CapE catalyzed reaction is positively modulated through
phosphorylation (Fig. 3e).
The role of the potential regulatory CapAB phosphorylation
sites was probed in a site-directed mutagenesis study. As
determined by CE quantification, replacing either Tyr76 of CapE
or the three C-terminal tyrosine residues Tyr290, Tyr293, and
Tyr329 with Phe diminished the activating effect of CapA1B1 on
CapE. The stimulatory effect of CapA1B1 on the conversion of
UDP-GlcNAc was completely abolished when all four tyrosine
residues were mutated to Phe, confirming their role as regulatory
phosphorylation sites on CapE (Supplementary Figure 7b).
CapA1 is a dual-function phosphodiesterase/kinase activator
protein. When purified lipid Icap was incubated in the presence of
CapA1, an additional lipid band was detected by TLC analysis
(Fig. 4a), which was not visible in the negative control with heat-
inactivated CapA1, indicating enzymatic conversion of the first
CP lipid precursor. Intriguingly, the reaction product displayed
an identical Rf value as the lipid carrier C55P. MALDI-TOF MS
analysis determined a mass of m/z 845.610 (negative mode;
[M–H]−) for the purified lipid product, confirming that CapA1
is able to catalyze the cleavage of the pyrophosphate linkage
within the lipid Icap intermediate to release C55P (Fig. 4b). Of
note, CapA1 was unable to cleave the peptidoglycan precursor
lipid IIPG, but was able to hydrolyze the WTA precursor lipid III
(Supplementary Figure 8). The facts that CapA1 interacts with
lipid-linked CP precursors, and exhibits phosphodiesterase
activity towards lipid Icap, implies additional functions for this
protein in CP biosynthesis, polymerization and attachment pro-
cesses that go beyond being a mere “transmembrane activator”.
Importantly, no cleavage of lipid Icap or lipid IIIWTA was observed
with the CapA1 paralogue CapA2 (Fig. 4a), revealing functional
differences between the two proteins.
CapA1 is anchored to the cytoplasmic membrane via two
transmembrane domains flanking an outside loop comprising
130 amino acids (Fig. 4c), which likely represents a dual function
sensory/catalytic domain involved in recognition and processing
of membrane-bound CP precursors.
As evidenced in previous research, CapA1 is crucial for
efficient capsule formation in S. aureus44. Corroborating these
studies, complementation with pCapA1 in trans enhanced CP
production in the serotype 8 strain MW2 (Fig. 4d). Strain MW2
carries a frameshift mutation in capA1 (cap5A) that results in
expression of a truncated version (171 aa) of the full-length gene
product (222 aa)45. In contrast, deletion of capA2 in S. aureus
Newman did not affect in vivo CP production (Fig. 4d). Similarly,
the deletion of cognate CapB kinases revealed, that capB1 but not
capB2 is required for CP production (Supplementary Figure 7c).
In spite of the functional redundancy and overlapping protein
target specificities of CapA1B1 and CapA2B2 observed in our
in vitro phosphorylation assays, the two kinase complexes clearly
have distinct roles in cell physiology.
In contrast to CapA1, CapA2 is not encoded within the cap5
operon, and does not exhibit phosphodiesterase activity towards
lipid Icap, which led us to conclude that CapA2 has a distinct
function in the biosynthesis of the bacterial cell envelope. More
recently, the S. aureus exopolysaccharide poly-N-acetyl-β-(1,6)-
glucosamine (PNAG; also referred to as polysaccharide inter-
cellular adhesin) has been reported to bind to the CapA2 receptor
loop46, suggesting that PNAG might represent a molecular signal
detected by CapA2. We therefore investigated the influence
of purified PNAG and CP5 on the autophosphorylation rate of
the CapAB complexes. As revealed by in vitro kinase assays,
CapA2-induced autophosphorylation of CapB2 was inhibited
in the presence of PNAG, as well as in the presence of CP5, in a
concentration-dependent manner (Supplementary Figure 9). In
contrast, CapA1-induced phosphorylation of CapB2 was not
diminished, indicating that the observed modulatory effect of
exopolysaccharide molecules is mediated via an interaction with
the transmembrane activator protein CapA2, and not via a direct
inhibitory interaction with the protein kinase CapB2. This finding
further substantiates differential roles for CapA1 and CapA2 in
cell envelope biosynthesis.
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LcpC catalyzes the ligation of CP to lipid II. Structural analysis
and phenotypic studies suggest that members of the LCP protein
family catalyze the transfer of undecaprenyl-linked intermediates
onto the C6-hydroxyl function of N-acetylmuramic acid in PG,
thereby promoting attachment of WTA and CP in Gram-positive
bacteria20,47. S. aureus encodes three LCP enzymes with semi-
redundant functions21. As deduced from knockout mutant stu-
dies, CP attachment is preferentially catalyzed by LcpC, though
LcpA and LcpB may partially compensate for the loss of LcpC21.
To investigate the proposed role of LcpC in vitro purified [14C]
lipid Icap was incubated with purified LcpC protein and lipid IIPG
as a potential acceptor substrate. In this setup, LcpC was able
to catalyze cleavage of the donor substrate lipid Icap and catalyze
attachment of the phosphoryl-sugar moiety to the ultimate PG
precursor lipid II (Fig. 5a), resulting in a reaction product
(LIIPG−14CCP) that migrates slower on TLC. Identical results
were obtained when [14C]-labeled lipid IIPG and non-labeled lipid
Icap were used as the reaction substrates (Fig. 5b), further
verifying the identity of the ligation product. Quantitative analysis
revealed that ~50% of the CP lipid precursor was attached to lipid
II (Fig. 5c). Strikingly, the LcpC-mediated transferase reaction
was significantly enhanced when CapA1 was included in the
reaction mixture, indicating cooperative action of the transmem-
brane activator/phosphodiesterase protein and LcpC (Fig. 5c).
CapA1 alone was unable to catalyze the attachment of the CP
precursor (Supplementary Figure 10a). Of note, LcpC was able to
catalyze hydrolytic cleavage of lipid Icap, but not of lipid IIPG, a
reaction that would likely be deleterious in vivo (Supplementary
Figure 10b, c).
Interestingly, PBP2 added posterior to the LcpC reaction
efficiently catalyzed the transglycosylation of lipid IIPG-CP
(Fig. 5a, b). The resulting polymerized PBP reaction product
is not extracted from the reaction mixture, thus lipid bands
vanish from the TLC. The antibiotic moenomycin, known to
inhibit the PBP2 catalyzed transglycosylation, fully blocked the
polymerization reaction (Fig. 5b). Importantly, LcpC was further
able to efficiently transfer the disaccharide of lipid IIcap and the
trisaccharide of the ultimate CP lipid intermediate lipid IIIcap to
lipid IIPG, as evidenced by the altered migration of the respective
ligation products (Rf= 0.26 and Rf= 0.22, respectively). Efficient
processing of ligation products by PBP2 shows that CP
attachment could occur in parallel to PG assembly (Fig. 5d).
Interestingly, antisense-RNA mediated depletion of CapA1 in a
triple Δlcp mutant was lethal, indicating that CapA1 hydrolysis of
C55P-coupled CP and WTA precursors contributes to rescue S.
aureus from the accumulation of toxic intermediates (Supple-
mentary Figure 10d) and further supports a functional link
between CapA1 and LcpC.
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Capsule biosynthesis is negatively controlled by PknB. As evi-
denced in previous research, the eukaryotic serine/threonine
kinase (ESTK) PknB of S. aureus is involved in the regulation of
cell envelope biogenesis processes48–50 and was more recently
shown to sense lipid IIPG51. Testing CapM in an in vitro kinase
assay showed PknB-mediated phosphorylation of the priming GT
(Fig. 6a). Moreover, quantitative analysis of the in vitro CapM-
catalyzed reaction revealed an up to 30% decrease in lipid Icap
synthesis when purified PknB kinase and ATP were included in
the reaction mixture, compared to a control reaction containing
heat-inactivated PknB, suggesting that ESTK signaling negatively
controls the activity of CapM (Fig. 6b). LC/MS-analysis revealed
PknB-mediated phosphotransfer onto Thr67, Thr128 and Thr134
of CapM (Supplementary Figure 11). Thr134 is highly conserved
among homologous bacterial glycosyltransferases, located in
proximity of the membrane interface and the amphipathic helices
D and I (Supplementary Figure 3c) and may thus be the most
promising candidate for a regulatory PknB-phosphorylation site
on CapM.
Intriguingly, the kinase protein CapB1 was also identified as
potential phosphorylation target of PknB (Fig. 6c), indicating the
possibility of kinase cross-talk. To further explore this finding, the
autophosphorylation activity of the CapA1B1 complex was
assessed in the presence of PknB. The overall phosphorylation
intensity of CapA1B1 was decreased by 34% in the presence of
active PknB (Fig. 6d), compared to the heat-inactivated negative
control, showing that PknB-mediated serine/threonine phosphor-
ylation inhibits CapB1 autophosphorylation on tyrosine. Thr8
was identified as the specific phosphorylation site on CapB1 by
LC/MS analysis (Supplementary Figure 12a) and a CapA1B1fus
phosphomimetic in which this Thr was exchanged to Glu resulted
in a significantly reduced CapB1 autophosphorylation (Supple-
mentary Figure 12b, c), suggesting that PknB-mediated phos-
phorylation interferes with the CapB1 activation by CapA141,52.
In contrast, an exchange of Thr8 to Ala did not affect CapA1B1fus
autophosphorylation (Supplementary Figure 12b,c).
To determine whether the observed inhibitory effect of PknB
in vitro would translate into an in vivo effect, we compared
CP5 production in S. aureus Newman and in an isogenic pknB
deletion mutant. Consistent with the proposed role of PknB as
negative regulator of CP biosynthesis, the amount of cell-
associated CP5 was 5-fold higher in the pknB mutant compared
to the parental strain and complementation of the ΔpknB mutant
in trans restored CP production to wild-type level (Fig. 6e).
The in vitro and in vivo data reveal that PknB signaling serves
to reduce CapM GT activity, as well as CapA1B1 autokinase
activity, allowing for a shutdown of CP production likely ensuring
a sufficient supply of precursors for PG formation, and thus
maintenance of cell wall architecture and function.
Discussion
Biosynthesis of the S. aureus CP shows similarity to the syntheses
of PG and WTA, in that all pathways share a pool of essential
precursors, i.e. the lipid carrier undecaprenyl-phosphate and
UDP-D-GlcNAc1,53. Since the availability of C55P within the
bacterial cell is limited22, distribution and prioritization for the
alternate metabolic pathways need to be tightly controlled in
time and space to ensure bacterial viability.
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Reversible protein phosphorylation appears an elegant
mechanism to ensure a coordinated and temporally controlled
flux of intimately shared cell envelope metabolites. Several bio-
synthetic enzymes involved in polysaccharide production have
been identified as endogenous substrates of bacterial tyrosine
kinases, for instance the UDP-glucose 6-dehydrogenases TuaA
and YwqF of Bacillus subtilis54, the homologous E. coli UDP-
glucose dehydrogenase Ugd55 and the UDP-ManNAc dehy-
drogenase CapO17 involved in S. aureus CP biosynthesis.
The fact that CapO, involved in the third CP reaction cascade
(Fig. 1), is a regulatory target of the CapAB kinase complex17, led
us to assume that additional checkpoints within the biosynthetic
pathway are also controlled by CapAB, which turned out to be
the case for CapE and CapM. Four tyrosine residues in the
dehydrogenase CapE were identified as the specific phosphor-
ylation sites, with Tyr76, Tyr290 and Tyr293 being widely con-
served among homologous proteins from different pathogens.
Interestingly, these residues are located in strategic functional
regions of CapE: next to the cofactor binding site, in close
proximity to the active site, and within a recently described
mobile loop (Fig. 3f). Crystal structure analysis identified this
mobile latch to connect two CapE protomers within the hex-
americ complex (trimer of dimers) and showed that the latch of
one dimerization partner is associated with the substrate-binding
domain of the contiguous CapE monomer, and vice versa, sug-
gesting that this mobile loop is involved in regulating the access of
the UDP-D-GlcNAc substrate to the active site56. Since contacts
to Tyr290 and Tyr293 appear to be involved in the interaction,
phosphorylation might induce conformational changes that
facilitate access of UDP-D-GlcNAc to the active site, thereby
increasing CapE enzymatic activity.
For the monotopic GT CapM, we identified the conserved
tyrosine residue at position 157 as the CapA1B1 regulatory
phosphorylation site which is in good agreement with the work
of Minic et al. (2007) and supports the hypothesis that phos-
phorylation of the equivalent site in the S. thermophilus
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phosphogalactosyl-transferase EpsE results in activation in vivo57.
A recent structural analysis showed, that the equivalent tyrosine
residue in PglC is involved in a hydrogen-bonding network that
establishes intramolecular interactions between helices A, F and
G37 (Supplementary Figure 3c), suggesting that the phosphory-
lated amino acid side chain may affect relative strengths of
hydrogen bonds and critical interactions in CapM.
Current hypotheses suggest a multifaceted role for BY-kinases
in bacterial exopolysaccharide production. BY-kinase signalling
may not only regulate the catalytic activity of polysaccharide
biosynthetic enzymes, but also ensure the correct cellular locali-
zation of protein targets58. Moreover, it has been suggested that
BY-kinases may interact with the export and polymerization
machinery to control the level of CP production and/or CP chain
length52,59. However, the exact mechanism through which this
control is exerted, as well as the molecular signal sensed, remains
enigmatic so far.
The phosphodiesterase activity of CapA1 described here is in
good agreement with previous studies demonstrating the release
of CP and WTA into the culture supernatant in LCP deletion
mutants of different species60–63. An lcpC deletion mutant of S.
aureus accumulated CP in the culture supernatant, indicating that
LcpC is the key LCP enzyme for attachment of CP to the pep-
tidoglycan in S. aureus21.
This study provides biochemical proof that LcpC catalyzes the
attachment of CP to PG. Importantly, CP lipid precursor cleavage
and transfer of the phosphosugar moiety were found to be
enhanced in the presence of CapA1, suggesting that the trans-
membrane activator cooperates with LcpC by forming an inter-
action complex, thereby modulating the attachment of CP to the
cell wall precursor. In line with this interpretation, Toniolo et al.
(2015) reported that the extracellular domain of the CapA1
homolog CpsC of Streptococcus agalactiae may modulate LCP-
mediated CP attachment in response to the phosphorylation state
of the BY kinase CpsD64.
The natural PG acceptor substrate of LcpC is elusive; possible
acceptor structures include the ultimate PG precursor lipid II, as
well as “nascent” and crosslinked PG. More recently, LcpA and
LcpB were shown to attach a shortened, soluble (C20P) WTA
precursor to a preformed “nascent PG” oligomer in vitro65, but
not to a lipid IIPG mimetic lacking the natural undecaprenyl tail.
In contrast, the biochemical analyses presented here clearly
demonstrate that CP is efficiently attached to lipid IIPG by the
LcpC enzyme, and that PBPs are able to polymerize the resulting
reaction product. With regard to the membrane localization of
both, substrates and enzymes, and the interdependence and
intimate connection of the enzymatic machineries, lipid IIPG
seems the most plausible acceptor.
CP lipid intermediates were further hydrolyzed by LcpC in the
absence of the acceptor substrate as predicted by structural
analysis of Cps2A of S. pneumoniae20, which was not observed
for LcpA and LcpB proteins65. In vitro, all three CP lipid inter-
mediates were efficiently processed by LcpC, although the prox-
imal full-length undecaprenyl-pyrophosphoryl-linked sugar
moiety appears sufficient for CP precursor recognition. Likewise,
the first C55P-linked sugar unit of the O-antigen repeat unit
contains the recognition information necessary for catalysis by
the O-antigen ligase WaaL66.
The biosyntheses of the cell envelope components PG, WTA
and CP have to be coordinated in time and space, since the
enzymatic machineries and their individual components are
functionally related to each other or intimately connected1,53.
The complex interplay between different cell envelope pathways
becomes evident upon inhibition of individual biosynthetic steps.
In analogy to the WTA biosynthesis in S. aureus, where late stage
biosynthetic genes have been shown to be conditionally essential
(“essential gene paradox”;67), Yother and co-workers reported
that deletion of the late stage CP biosynthesis genes, responsible
for side chain assembly, polymerization or transport (cps2K,
cps2J, and cps2H) in Streptococcus pneumoniae, is lethal68. Since
the capsule is not required for cell viability per se, the damage to
the cell envelope is most likely due to an inhibitory effect on PG
biosynthesis, resulting from sequestration of CP lipid inter-
mediates probably reducing the undecaprenyl-phosphate level to
a critical point where PG synthesis is affected. Since we found
CapA1 to hydrolyze CP lipid intermediates even in the absence of
LCP proteins and that depletion of CapA1 in a S. aureus Δlcp
triple mutant was lethal, we conclude that CapA1-mediated
cleavage of dead-end lipid-linked products might serve as a rescue
mechanism counteracting depletion of C55P to critical levels.
The ESTK PknB is another important player in the orches-
tration of cell wall polymer biosynthesis and has been implicated
in coordinating PG cross-wall formation, autolysis and cell divi-
sion in S. aureus48–50. Our findings that PknB downregulates
CapM and with the BY-kinase CapA1B1 operating in an antag-
onal manner underpins the importance of CapM as crucial
enzymatic checkpoint. Moreover, in vitro kinase assays indicate
that PknB-mediated phosphotransfer onto CapB1 modulates
the activity of the CapA1B1 BY-kinase complex itself, thus
identifying another activity by which PknB may exert control on
CP biosynthesis. Cross-phosphorylation of ESTKs and BY-
kinases has also been reported in B. subtilis69. The CapB homo-
log PtkA was identified as in vitro phosphorylation target of the
ESTK PrkC69. Moreover, PtkA autophosphorylation in vivo
was strongly enhanced in a ΔprkC strain, suggesting that PtkA
BY-kinase activity is negatively regulated by PrkC-mediated
phosphotransfer70.
Corroborating the in vitro results, CP production was sub-
stantially elevated in a pknB deletion mutant of S. aureus. Besides
decreasing the activity of CP biosynthesis proteins by direct
phosphorylation, PknB kinase activity may serve to increase the
cellular concentration of UDP-MurNAc-pentapeptide and lipid
IIPG71, cell wall metabolites that were identified as inhibitors of
CapD enzymatic activity19. Moreover, PknB signaling was
reported to influence the transcription of the cap5 gene cluster72,
suggesting that this sensor kinase is part of a multilayered signal-
transduction network that coordinates CP formation in space
and time.
The finding that CP and PG production are inversely con-
trolled by PknB further substantiates a key role for PknB in the
coordinate regulation of Gram-positive cell surface glycopoly-
mers. In exponentially growing cells, PknB-mediated Ser/Thr
phosphorylation positively controls PG biosynthesis, while
exerting negative control on CP production (Fig. 7).
With respect to biosynthesis of the S. aureus CP, the CapA1B1
complex may be particularly important for short-term regulation.
More recently, Elsholz and co-workers showed that exopoly-
saccharide (EPS) production in Bacillus subtilis is subject to a
positive feedback loop that ties the synthesis of the polymer to its
own concentration46. Regulation of EPS synthesis is mediated by
the EpsAB tyrosine kinase complex, whereby direct recognition of
EPS by the extracellular domain of the membrane component
EpsA seems to result in stimulation of kinase activity46.
The activator/phosphodiesterase CapA1 directly and specifi-
cally interacts with lipid-bound CP precursors, and CapA1B1
signaling stimulates the activity of CP biosynthetic enzymes,
triggering enhanced CP production in late-exponential and
stationary phase (Fig. 7).
S. aureus PknB specifically interacts with lipid IIPG, likely
responding to cellular pool levels of the ultimate peptidoglycan
precursor51. It is thus conceivable that in order to balance the
pool levels of the lipid IIPG acceptor and the CP donor substrate,
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which are both built on the lipid carrier C55P, PknB and
CapA1B1 antagonistically control biosyntheses to ensure vital
cycling of the essential C55P lipid carrier. In addition, CapA1
might contribute to the correct localization of the CP assembly
machinery, as proposed for S. agalactiae64, which has to integrate
precursor transport and CP polymerization. This interaction
protein network thus appears to contribute to the spatiotemporal
coordination of CP biosynthesis with PG synthesis (Fig. 7), ren-
dering proteins such as CapA1 and LcpC, exposed at the cell
surface and devoid of eukaryotic homologs, potentially attractive
antibacterial or antivirulence targets.
Methods
Strains. S. aureus Newman NCTC8178 was maintained on blood or lysogeny
broth (LB; Oxoid) agar. Escherichia coli strains BL21 and C43 used for over-
expression of recombinant His6-tag fusion proteins were maintained on LB-agar
plates containing 50 µg ml−1 ampicillin or 25 µg ml−1 kanamycin. CP5 production
was quantified from S. aureus cultivated on Columbia medium supplemented with
2% NaCl and 1.5% agar. The Newman ΔpknB mutant was kindly provided by Dr.
Knut Olsen (Wuerzburg, Germany), and RN4220 carrying pCapA1 was provided
by Dr. Gabriele Bierbaum (Bonn, Germany)44. S. aureus strain MW2 (NRS123)
and strains from the Nebraska transposon mutant library73 were obtained from the
Network on Antimicrobial Resistance in Staphylococcus aureus program, which
was supported by the National Institute of Allergy and Infectious Diseases of the
National Institutes of Health (contract HHSN272200700055C). The Nebraska
library is comprised of derivatives of the serotype 5 strain USA300 LAC (cured of
three plasmids) in which individual nonessential genes were disrupted by the
insertion of the mariner transposon (Tn) bursa aurealis and includes mutants
in capA2 (NE1286), capB2 (NE75), capA1 (NE302a), and capB1 (NE135).
Construction of cap deletion mutants is described in the Supplementary Methods.
The pknB and Tn mutants were maintained on tryptic soy agar (TSA) plates with
5 µg ml−1 erythromycin, and pCapA1 was maintained in S. aureus cultivated
on TSA with 10 µg ml−1 chloramphenicol. S. aureus Newman ΔlcpABC mutants
were kindly provided by Dr. Olaf Schneewind (Chicago, USA)21 maintained on
LB-agar plates. S. aureus strains carrying the plasmid pEPSA5 or the antisense
plasmid pEPSA5-capA1AS were maintained on TSA-agar plates supplemented
with 34 µg ml−1 chloramphenicol.
Plasmid construction and site-directed mutagenesis. Oligonucleotide primers
were purchased from Eurofins MWG Operon (Germany). Primer pairs used for
amplification of genomic sequences encoding capA1, capA2, capB1, capB2,
capA1B1fus, capA2B2fus, capA1as, capC1, capC2, capI, capL, capN, capM and lcpC
are listed in Supplementary Table 1. PCR reactions were carried out using Phusion
DNA polymerase (NEB) and genomic DNA of the serotype 5 strain S. aureus
Newman as template. PCR products were digested with type II restriction endo-
nucleases (NEB; Supplementary Table 1) and ligated (T4 DNA ligase, Roche) with
appropriately restricted expression vectors (Novagen). The PCR amplicon of the
gene capN was inserted into pET24a. The vector pET21b was utilized for cloning
of the capI and capL genes. The antisense fragment of capA1 was inserted into
pEPSA5. All other amplicons were introduced into pET28a. The resulting plasmids
(Supplementary Table 2) were confirmed by DNA sequencing (Sequiserve,
Germany). Plasmids pET24a-capD, pKBK50d, pET5F1.1, pKBK6a, pET28a-pglF
and pET52b-pknB used for overexpression of CapD-His6, CapE-His6, CapF-His6,
CapG-His6, PglF-His6 and PknB-His6 have been described previously13,19. To
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Fig. 7 Model for the regulation of CP biosynthesis and the attachment to PG in S. aureus. The CapA1B1 tyrosine complex (blue) positively controls multiple
enzymatic checkpoints to orchestrate CP biosynthesis and precursor consumption during late exponential growth phase (white box). By catalyzing tyrosine
phosphorylation (blue ´P´) of biosynthetic enzymes CapE, CapO and CapM, CapA1B1 positively controls the synthesis of both soluble and lipid-linked CP
precursors. The membrane-anchored component CapA1 possesses a dual function; CapA1 recognizes lipid-bound CP building blocks and catalyzes the
cleavage of the pyrophosphate linkage, releasing the essential isoprenoid lipid carrier C55P. CP transfer is catalyzed by LcpC (red), which uses the ultimate
peptidoglycan (PG) precursor lipid IIPG as an acceptor substrate. During exponential growth phase (grey shading), the insertion of new PG material (LIIPG)
into the cell wall network is increased; UDP-GlcNAc and C55P are preferably channeled into PG and WTA biosynthesis, while CP production is low. The
Ser/Thr kinase PknB (green) contributes to the control of cell wall biosynthesis and cell division. Control of CP formation during ongoing PG synthesis is
achieved by PknB via Ser/Thr phosphorylation (green ´P´). PknB negatively controls the activity of the priming glycosyltransferase CapM to regulate the
initial C55P-consuming reaction within the CP biosynthetic pathway. Furthermore, PknB cross-talks with the CapAB complex, thus allowing control of
the CP biosynthetic machinery on multiple levels, in response to the status of PG biosynthesis. The model highlights central biosynthetic precursors as
important signal molecules situated at the interface of different pathways, integrated in feedback loops to control biosyntheses and the flux of shared
precursors
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enable expression of N-terminally His6-tagged CapA1B1 and CapA2B2 fusion
proteins, the constructs capA1B1fus and capA2B2fus were amplified using the
primer pairs capA1_F and capB1_R, and capA2_F and capB2_R, respectively. The
QuikChange Lightning Mutagenesis Kit (Stratagene) was used according to the
manufacturer’s instructions to remove the stop codon of capA by site-directed
mutagenesis (TTA > GCA); the respective mutagenesis primers (capA1B1fus_-
mut_F, capA1B1fus_mut_R) and capA2B2fus_mut_F and capA2B2fus_mut_R
(TAA > TAT) are given in Supplementary Table 1. Site-directed mutagenesis of
plasmid pET28a-capM was performed to introduce amino acid exchanges Tyr75
(TAT) > Phe (TTT) (primers: capM_mutY75_F, capM_mutY75_R) and Tyr157
(TAC) > Phe (TTC) (capM_mutY157_F, capM_mutY157_R) in CapM. Likewise,
plasmid pKBK50d was mutated to introduce amino acid exchanges Tyr76 (TAC) >
Phe (TTC) (capE_mutY76_F, capE_mutY76_R), Tyr290/293 (TAT) > Phe (TTT)
(capE_mutY290/293_F, capE_mutY290/293_R), and Tyr329 (TAT) > Phe (TTT)
(capE_mutY329_F, capE_mutY329_R) into CapE. Site-directed mutagenesis of
plasmid pET28a-capA1B1 was performed to introduce amino acid exchanges Thr8
(ACA) > Glu (GAA) (primers: capA1B1fus_mutT8E_F, capA1B1fus_mutT8E_R)
and Thr8 (ACA) > Ala (GCA) (primers: capA1B1fus_mutT8A_F and capA1B1-
fus_mutT8A_R) into CapA1B1fus. In order to produce a CapB2_T8E mutant, site-
directed mutagenesis of plasmid pET28a-capB2 was performed using the primer
pair capB2_mutT8E_F and capB2_mutT8E_R to introduce an amino acid
exchange Thr8 (ACA) > Glu (GAA). PCR-mediated base pair exchange was con-
firmed by sequencing. The resulting plasmids, which were utilized for expression
and purification of CapM and CapE mutant proteins containing single or multiple
Tyr to Phe exchanges, are listed in Supplementary Table 2. pCapA1 was transduced
from S. aureus RN4220 to strain MW2 with phage 11, with selection on medium
containing 10 µg ml−1 chloramphenicol. S. aureus Newman ΔlcpABC was trans-
formed by electroporation74 with pEPSA5-capA1AS purified from E. coli DC10B,
with selection on TSA containing 2.5% glucose and 34 µg ml−1 chloramphenicol.
Expression of the appropriate antisense fragment was induced on TSA-agar plates
containing 500 mM xylose.
Overexpression and purification of recombinant proteins. E. coli strain BL21
(DE3) (Promega) was used as host for the recombinant expression of cytoplasmic
enzymes (CapB1-His6, CapB2-His6, CapC1-His6, CapC2-His6, CapE-His6, CapF-
His6, CapG-His6, CapO-His6,CapP-His6 and PglF-His6) and E. coli strain C43
(DE3) (Promega) was used for the recombinant expression of integral membrane
or membrane associated proteins (CapA1-His6, CapA2-His6, CapAB-His6 fusion
constructs, CapI-His6, CapL-His6, CapM-His6, CapD-His6, LcpC-His6 and Strep-
tagged PknB. E. coli strain BL21 (DE3) cells were grown at 37 °C in lysogeny broth
(LB; Oxoid) and E. coli C43 (DE3) cells were grown at 30 °C in double-strength
yeast extract-tryptone broth (2YT, Difco) containing the appropriate selective
antibiotic (50 µg ml−1 ampicillin or 25 µg ml−1 kanamycin). At an OD600 of 0.6,
IPTG was added at a final concentration of 0.5 mM to induce expression of the
recombinant protein. Expression times and temperatures were optimized for the
individual constructs to ensure high yields of the different fusion proteins. The
cultures for overexpression of CapA1, CapA2, CapAB fusion constructs, CapD,
CapI, CapL, CapN, LcpC and PknB were induced at 20 °C for 16 h. All other E. coli
BL21 (DE3) cultures and the E. coli C43 (DE3) cultures for the expression of CapM
were induced at 30 °C for 4 h. After induction, cells were harvested (15 min, 4 °C,
7000 × g) and resuspended in lysis buffer (50 mM Tris-HCl, 300 mM NaCl, pH
7.5), which was supplemented with 1% (v/v) Triton X-100 (Sigma-Aldrich) for
purification of CapA1, CapA2, CapAB fusion constructs and CapN or with 29 mM
n-dodecyl-β-D-maltoside (DDM, Glycon Biochemicals) for purification of CapD,
CapI, CapL, CapM and LcpC. Lysozyme (250 µg ml−1), DNase (50 µg ml−1) and
RNase (10 µg ml−1) (Sigma-Aldrich) were added to the suspension; cells were
incubated on ice for 30 min and sonicated. Cell debris was removed by cen-
trifugation (20 min, 4 °C, 21,000 × g).
The supernatant was incubated with Ni-NTA-agarose slurry (Qiagen,
Germany) for 2 h at 4 °C under gentle stirring. The mixture was then loaded onto a
column support. After washing with lysis buffer, weakly bound material was
removed with 10 and 20 mM imidazole. Recombinant proteins were eluted with
buffer containing 300 mM imidazole. Five 500-µl fractions were collected each and
stored in 30% (v/v) glycerol at −20 °C; preparations of CapE were dialyzed against
10 mM potassium phosphate buffer (KPi), pH 7.5 before storage. For PknB
purification the pellet was resuspended in lysis buffer containing 1% (v/v) Triton
X-100 and the suspension was incubated on ice for 1 h. Cell debris was spun down
(20 min, 4 °C, 34,000 x g) and the clear supernatant was loaded onto a Strep-tactin
agarose column (IBA, Germany). The column was washed twice with lysis buffer
and PknB was eluted with Strep-tactin elution buffer (IBA, Germany). Purity of
elution fractions was assessed by SDS-Page (NuPAGE; Invitrogen); protein
concentrations were measured using Bradford reagent (Bio-Rad, Germany).
Expression and purification of CapA1B1fus, CapE and CapM protein variants were
carried out as described for the wild-type proteins.
In vitro syntheses of soluble CP precursors. UDP-D-GlcNAc and cofactors
for enzyme assays were obtained from Sigma-Aldrich. Synthesis of the precursor
UDP-2-acetamido-2,6-dideoxy-D-xylo−4-hexulose for mass spectrometric analysis
was performed with a recombinant truncated version of the enzyme PglF from
C. jejuni, as previously described19. The PglF reaction product was used as
substrate for reconstitution of CapN catalytic activity. For this purpose, PglF
reactions were carried out overnight and quenched by heating (5 min, 95 °C).
CapN catalyzed synthesis of UDP-D-FucNAc was carried out in a total volume
of 40 µl. CapN (12 µg) was incubated in the presence of ~3 mM UDP-2-acetamido-
2,6-dideoxy-D-xylo−4-hexulose, 1.875 mM NADPH, 8% (v/v) Triton X-100 and
10 mM KPi, pH 7.5, for 2 h at 30 °C. Synthesis of larger quantities of soluble
capsule precursors for MALDI-TOF MS analysis was achieved by a 10-fold upscale
of the synthesis reaction.
Alternatively, synthesis of UDP-D-FucNAc was performed in an one-pot-
assay containing 4 µg CapD, 4 µg CapN, 2 mM UDP-D-GlcNAc, 2 mM NADPH
and 0.5 mM NADP in 50 mM Tris-HCl, 10 mM MgCl2, pH 7.5, in a total volume
of 30 µl. UDP-L-FucNAc was synthesized by incubating CapE, CapF and CapG in
presence of 2 mM UDP-D-GlcNAc, 2 mM NADPH and 0.5 mM NADP in 50 mM
Tris-HCl, 10 mM MgCl2, pH 7.5.
The third soluble precursor UDP-D-ManNAcA was synthesized by incubating
2 mM UDP-D-GlcNAc with CapO and CapP (4 µg each), 6 mM NAD+ and 0.5
mM dithiothreitol (DTT; Sigma-Aldrich) in 50 mM Tris-HCl, 10 mM MgCl2, pH
7.5. All enzymatic synthesis reactions were quenched by heating 5 min, 90 °C).
In vitro modulation of CapE catalytic activity by CapAB. The influence of
CapAB-mediated tyrosine phosphorylation on CapE catalytic activity was exam-
ined in vitro using purified recombinant proteins. Assays were performed in a
total volume of 100 µl containing 17 µg of CapE (or of a CapE protein variants) and
8.5 µg of purified CapAB kinase complex. The enzymes were incubated in the
presence of 3 mM UDP-D-GlcNAc and 1mM ATP, in 10 mM KPi, 10 mM MgCl2,
pH 7.5 supplemented with 1 mM DTT, for 30 min at 30 °C. Reactions were
quenched by heating (5 min, 90 °C), then subjected to capillary electrophoresis
(CE) analysis19. Control reactions were performed with heat-inactivated (10 min,
100 °C) CapAB protein.
MALDI-TOF mass spectrometric analysis. Soluble capsule precursors were
purified by RP18-HPLC19, and cleaved C55P intermediates were purified by pre-
parative TLC. Lipid spots were visualized using iodine vapour and extracted off
the silica plates with methanol. Samples were spotted onto a ground steel MALDI-
TOF target plate and allowed to dry at room temperature. Subsequently, each
sample was overlaid with 1 µl of matrix (saturated solution of 6-Aza-2-thiothymine
in 50% (v/v) ethanol, 10 mM diammonium hydrogen citrate) and air dried at room
temperature again. Spectra were recorded either in the reflector negative mode
within a mass range from 300 to 3000 Da (soluble capsule precursors) or in the
linear negative mode within a mass range from 400 to 3000 Da (lipid inter-
mediates), at a laser frequency of 9 Hz on a Biflex III mass spectrometer (Bruker
Daltonics). Data analysis was performed using flexAnalysis software (Bruker
Daltonics).
In vitro kinase assays. In vitro BY-kinase assays were carried out in a total
volume of 10 µl containing either 0.5 µg of CapA and CapB, or 2 µg of a CapAB
protein fusion construct. For identification of protein substrates, 2 µg of a
recombinant target protein were added. The proteins were incubated in the
presence of 10 μCi γ-labeled [33P]ATP (~300 nM; Hartmann Analytic) in 50 mM
Tris-HCl, 10 mM MgCl2, pH 7.5 supplemented with 0.5 mM DTT, 0.5 mM EDTA
and 10 µM ATP. Assays with CapAB protein variants were carried out as described
for the wild-type proteins.
For identification of PknB protein substrates, purified PknB (0.5 µg) was
incubated in presence of 3 mM MnCl2 in the reaction mixture described above.
Cross-phosphorylation of CapAB by PknB was assessed analogously.
After 30 min of incubation at 30 °C, reactions were stopped by addition of
4x LDS sample buffer (Invitrogen), and analyzed by SDS-PAGE (NuPAGE,
Invitrogen). Radioactive protein bands were visualized using a storage phosphor
screen in a Storm imaging system (GE Healthcare). A detailed description of
the identification of phosphorylation sites by nanoLC-MS/MS is given in
the Supplementary Methods.
In vitro phosphatase assays. CapC phosphatase activity was examined in vitro by
the addition of CapC1 or CapC2 (2 µg each) with 2 mM MnCl2 to the CapAB
in vitro kinase assays (see above) and subsequent heat-inactivation. After incu-
bation for 1 h at 30 °C, phosphatase reaction was stopped by the by addition of
4x LDS sample buffer (Invitrogen), and analyzed by SDS-PAGE (NuPAGE,
Invitrogen). Radioactive protein bands were visualized using a storage phosphor
screen in a Storm imaging system (GE Healthcare).
In vitro syntheses of lipid Icap, lipid IIcap, and lipid IIIcap. Lipid Icap synthesis
was carried out in a total volume of 50 µl containing 5 nmol C55P (Larodan,
Sweden), 2 mM UDP-D-GlcNAc, 10 mM NADPH, 0.5 mM NADP and 0.6% (v/v)
DMSO in 50 mM Tris-HCl, 10 mM MgCl2, pH 7.5. The reaction was initiated
by the addition of 4 µg of biosynthetic enzymes CapD, CapN and CapM, and
incubated for 16 h at 30 °C.
To assess the influence of different detergents and phospholipids on CapM
activity, newly synthesized UDP-D-FucNAc (described above) was incubated with
4 µg CapM, 5 nmol C55P in a reaction mixture containing 50 mM Tris-HCl, 10 mM
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MgCl2, pH 7.5 supplemented with an appropriate amount of triton X-100,
n-dodecyl-β-D-maltoside (DDM), n-lauroyl sarcosine (LS), dimethylsulfoxide
(DMSO), dioleoylphosphatidylglycerol (DOPG) or cardiolipin (CL). To investigate
the modulatory effect of CapAB on CapM activity 4 µg CapAB and 10 mM ATP
were added to the CapM reaction mixture. To assess the influence of PknB on
CapM activity in vitro, 1 µg PknB was added to the CapM reaction mixture
supplemented with 2 mM MnCl2 and 10 mM ATP.
The second precursor lipid IIcap was synthesized in a total volume of 50 µl by
incubating the capsule biosynthesis proteins CapE, CapF, CapG and CapL (4 µg
each) in the presence of 2 nmol purified lipid Icap and 2 mM UDP-D-GlcNAc, 2
mM NADPH, 0.5 mM NADP and 0.6% (v/v) DMSO in 50 mM Tris-HCl, 10 mM
MgCl2, pH 7.5.
Lipid IIIcap was synthesized by incubating 2 nmol purified lipid IIcap with CapO,
CapP and CapI (4 µg each) and 2 mM UDP-D-GlcNAc, 6 mM NAD+, 0.5 mM
dithiothreitol (DTT; Sigma-Aldrich) in 50 mM Tris-HCl, 10 mM MgCl2, pH 7.5.
Synthesized CP precursors were extracted from the reaction mixture with an equal
volume of n-butanol/pyridine acetate, pH 4.2 (2:1, v/v) and analyzed by TLC on
silica plates (Merck) according to Rick (chloroform, methanol, water, ammonium
hydroxide, 88:48:10:1)75. Nisin was added at a molar ratio of 2:1 with respect to the
lipid precursor prior to the extraction procedure. Reaction mixtures were extracted
and unbound lipids were analyzed by TLC. For mass spectrometric analysis of lipid
intermediates see Supplementary Methods.
For synthesis of [14C]-labeled lipid-bound precursors, the assays were further
supplemented with 0.333 nmol UDP-D-[14C]GlcNAc (Hartmann Analytic,
Germany). Radiolabeled spots were visualized using a storage phosphor screen in a
Storm imaging system (GE Healthcare). Non-radiolabeled lipid intermediates were
analyzed using PMA staining reagent (2.5% (w/v) phosphomolybdate, 1% (w/v)
ceric sulfate, 6% (v/v) sulfuric acid). Isolation of small quantities of CP precursors
was achieved by synthesis and subsequent purification via preparative TLC. To this
end, lipid spots were visualized using iodine vapour and material was scratched off
the silica plates. Lipids were extracted by incubation in 100 µl of methanol for 60
min. Larger quantities of CP precursor were purified using high-performance
liquid chromatography (HPLC) over a DEAE-FF (5 ml; GE Healthcare) and eluted
in a linear gradient from chloroform/ methanol/ water (2:3:1) to chloroform,
methanol, 300 mM ammonium bicarbonate (2:3:1).
CapA1 catalyzed cleavage of lipid-bound CP precursor. For reconstitution of the
CapA1 mediated cleavage of the pyrophosphate-linkage of lipid-linked cell wall
intermediates, purified CapA1 (8 µg) was incubated with 2 nmol lipid Icap, lipid
IIIWTA, lipid IIPG in 10 mM MgCl2 and 50 mM Tris-HCl, pH 7.5. After incubation
for 16 h at 30 °C, cleavage products were extracted from the reaction mixture with
an equal volume of n-butanol/pyridine acetate, pH 4.2 (2:1, v/v) and analyzed by
TLC on silica plates (Merck) according to Rick (chloroform, methanol, water,
ammonium hydroxide, 88:48:10:1) and visualized by PMA staining75.
In vitro LCP assays. For reconstitution of the CP ligation reaction purified lipid
Icap or [14C]lipid Icap was incubated in the presence of LcpC (4 µg), using 2 nmol of
purified lipid IIPG or [14C]lipid IIPG as acceptor substrate in a 50 µl reaction
mixture with 0.6% DMSO, 18 µg DOPG, 10 mM MgCl2 in 50 mM MES buffer, pH
5.5. Synthesis and purification of the acceptor substrate lipid II is described in the
supplementary methods. If indicated, assays additionally contained 4 µg of CapA1.
After incubation for 16 h at 30 °C, samples were analyzed by TLC, followed by
phosphoimaging. Polymerization of LcpC reaction products were catalyzed by the
subsequent addition of PBP2 with 2 mM CaCl2 to the LCP reaction mixture,
followed by incubation at 30 °C for 1 h. Moenomycin (MOE) was used to block the
PBP2 catalyzed reaction and added at a final concentration of 10 µM. For eva-
luation of LcpC mediated hydrolysis of CP precursor in the absence of the acceptor
substrate, 2 nmol of the individual lipid-linked precursor was incubated with 4 µg
LcpC, 18 µg DOPG, 10 mMMgCl2 and 0.6% DMSO in 50 mMMES buffer, pH 5.5.
After incubation for 16 h at 30 °C, samples were analyzed by TLC and visualized by
PMA staining.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
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